PRLD Stock Analysis: Buy, Sell, or Hold?
PRLD - Prelude Therapeutics Incorporated
$3.07
0.02 (0.66%)
▲
5d:
-2.85%
30d:
+11.23%
90d:
+25.31%
BUY
HIGH Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 05, 2026
Smart Money Accumulation
PRLD is down 18.9% this week, but smart money is accumulating calls. Top strike: $2.5 2026-04-17 with 5 OI. Call ratio: 100% View Scanner →
Strength: 10.0/10
Get Alerted When PRLD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PRLD shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: PRLD shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: PRLD is currently trading at $3.07, which is considered fair relative to its 30-day fair value range of $2.77 to $3.39. From a valuation perspective, the stock is trading at a discount (Forward PE: -7.0) compared to its historical average (34.9). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PRLD is in a strong uptrend. Immediate support is located at $2.83, while resistance sits at $3.60.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $5.17 (+68.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PRLD is in a strong uptrend. Immediate support is located at $2.83, while resistance sits at $3.60.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $5.17 (+68.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$2.77 -
$3.39
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
81.5%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 68.3% below Wall St target ($5.17)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Fair Price Analysis
30-Day Fair Range
$2.77 -
$3.39
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$0.60
(19.5%)
Support & Resistance Levels
Support Level
$2.83
Resistance Level
$3.60
Current Trend
Strong Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.98
Wall Street Target
$5.17
(+68.3%)
Revenue Growth (YoY)
41.0%
PE vs Historical
-7.0 vs 34.9
CHEAP
Share & Embed Analysis
Last updated: March 30, 2026 6:33 PM ET
Data refreshes hourly during market hours. Next update: 7:33 PM
Data refreshes hourly during market hours. Next update: 7:33 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PRLD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 48 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 67 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 48 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 57 HOLD |
